Chronic Carbamazepine Administration Reduces N-Methyl-D-Aspartate Receptor-Initiated Signaling via Arachidonic Acid in Rat Brain

Biological Psychiatry

Volumn 62, Issue 8, 2007, Pages 934-943

  Basselin, Mireille ^a   Villacreses, Nelly E ^a   Chen, Mei ^a   Bell, Jane M ^a   Rapoport, Stanley I ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Arachidonic acid; bipolar disorder; carbamazepine; NMDA; phospholipase A2; prostaglandin E2

Indexed keywords

ARACHIDONIC ACID; CARBAMAZEPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROSTAGLANDIN E2; THROMBOXANE B2;

ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; MALE; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMANIC AGENTS; ARACHIDONIC ACID; BRAIN; CARBAMAZEPINE; DINOPROSTONE; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, NONESTERIFIED; MALE; RATS; RATS, INBRED F344; RECEPTORS, N-METHYL-D-ASPARTATE; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; THROMBOXANE B2;

EID: 34748883658     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.04.021     Document Type: Article

References (98)

1. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7 suppl 1 (2002) S71-S80
2. Zarate Jr. C.A., Du J., Quiroz J., Gray N.A., Denicoff K.D., Singh J., et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: Role of the glutamatergic system. Ann N Y Acad Sci 1003 (2003) 273-291
3. Michael N., Erfurth A., Ohrmann P., Gossling M., Arolt V., Heindel W., et al. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl) 168 (2003) 344-346
4. Castillo M., Kwock L., Courvoisie H., and Hooper S.R. Proton MR spectroscopy in children with bipolar affective disorder: Preliminary observations. AJNR Am J Neuroradiol 21 (2000) 832-838
5. Itokawa M., Yamada K., Iwayama-Shigeno Y., Ishitsuka Y., Detera-Wadleigh S., and Yoshikawa T. Genetic analysis of a functional GRIN2A promoter (GT)n repeat in bipolar disorder pedigrees in humans. Neurosci Lett 345 (2003) 53-56
6. Martucci L., Wong A.H., De Luca V., Likhodi O., Wong G.W., King N., et al. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res 84 (2006) 214-221
7. Mundo E., Tharmalingham S., Neves-Pereira M., Dalton E.J., Macciardi F., Parikh S.V., et al. Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry 8 (2003) 241-245
8. Scarr E., Pavey G., Sundram S., MacKinnon A., and Dean B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 5 (2003) 257-264
9. McCullumsmith R.E., Kristiansen L.V., Beneyto M., Scarr E., Dean B., and Meador-Woodruff J.H. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127 (2007) 108-118
10. Gascon S., Deogracias R., Sobrado M., Roda J.M., Renart J., Rodriguez-Pena A., et al. Transcription of the NR1 subunit of the N-methyl-D-aspartate receptor is down-regulated by excitotoxic stimulation and cerebral ischemia. J Biol Chem 280 (2005) 35018-35027
11. Ciabarra A.M., Sullivan J.M., Gahn L.G., Pecht G., Heinemann S., and Sevarino K.A. Cloning and characterization of chi-1: A developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J Neurosci 15 (1995) 6498-6508
12. Sucher N.J., Akbarian S., Chi C.L., Leclerc C.L., Awobuluyi M., Deitcher D.L., et al. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J Neurosci 15 (1995) 6509-6520
13. Das S., Sasaki Y.F., Rothe T., Premkumar L.S., Takasu M., Crandall J.E., et al. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 393 (1998) 377-381
14. Dumuis A., Sebben M., Haynes L., Pin J.P., and Bockaert J. NMDA receptors activate the arachidonic acid cascade system in striatal neurons. Nature 336 (1988) 68-70
15. 2 in brain cortical cultures. Biochem J 310 (1995) 83-90
16. 2 and somatostatin release from rat cortical neurons in primary cultures. Eur J Pharmacol 225 (1992) 253-262
17. 2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 360 (1999) 609-615
18. Shimizu T., and Wolfe L.S. Arachidonic acid cascade and signal transduction. J Neurochem 55 (1990) 1-15
19. Rapoport S.I. In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 16 (2001) 243-261
20. Rapoport S.I. In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. J Pediatr 143 (2003) S26-S34
21. Robinson P.J., Noronha J., DeGeorge J.J., Freed L.M., Nariai T., and Rapoport S.I. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: Review and critical analysis. Brain Res Brain Res Rev 17 (1992) 187-214
22. 2 gene and bipolar affective disorder. Psychiatr Genet 5 (1995) 177-180
23. 2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res 1103 (2006) 164-172
24. Chiu C.C., Huang S.Y., Su K.P., Lu M.L., Huang M.C., Chen C.C., et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol 13 (2003) 99-103
25. Calabrese J.R., Bowden C., and Woyshville M.J. Lithium and the anticonvulsants in the treatment of bipolar disorder. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven, New York 1099-1111
26. Bowden C.L., and Karren N.U. Anticonvulsants in bipolar disorder. Aust N Z J Psychiatry 40 (2006) 386-393
27. Goodnick P.J. Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother 7 (2006) 401-410
28. Post R.M., Ketter T.A., Uhde T., and Ballenger J.C. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: Principles and practice. CNS Drugs 21 (2007) 47-71
29. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., and Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: A possible common effect of mood stabilizers. J Neurochem 77 (2001) 796-803
30. Chang M.C., Grange E., Rabin O., Bell J.M., Allen D.D., and Rapoport S.I. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett 220 (1996) 171-174 Erratum in: Neurosci Lett 1997, 1222:1141
31. Bazinet R.P., Rao J.S., Chang L., Rapoport S.I., and Lee H.J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: Relevance to bipolar disorder. Biol Psychiatry 59 (2006) 401-407
32. Bazinet R.P., Weis M.T., Rapoport S.I., and Rosenberger T.A. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: Relevance to bipolar disorder. Psychopharmacology (Berl) 184 (2006) 122-129
33. 2 is a target for chronic lithium in rat brain. Neuroreport 10 (1999) 3887-3890
34. 2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry 56 (2004) 248-254
35. 2 concentration in rat brain. Mol Psychiatry 7 (2002) 845-850
36. Bosetti F., Weerasinghe G.R., Rosenberger T.A., and Rapoport S.I. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem 85 (2003) 690-696
37. Rapoport S.I., and Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?. Arch Gen Psychiatry 59 (2002) 592-506
38. Basselin M., Chang L., Bell J.M., and Rapoport S.I. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31 (2006) 1659-1674
39. Lampe H., and Bigalke H. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1 (1990) 26-28
40. Lancaster J.M., and Davies J.A. Carbamazepine inhibits NMDA-induced depolarizations in cortical wedges prepared from DBA/2 mice. Experientia 48 (1992) 751-753
41. Sofia R.D., Gordon R., Gels M., and Diamantis W. Comparative effects of felbamate and other compounds on N-methyl-D-aspartic acid-induced convulsions and lethality in mice. Pharmacol Res 29 (1994) 139-144
42. Hough C.J., Irwin R.P., Gao X.M., Rogawski M.A., and Chuang D.M. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther 276 (1996) 143-149
43. 2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 38 (1999) 1349-1359
44. Bown C.D., Wang J.F., and Young L.T. Attenuation of N-methyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience 117 (2003) 949-955
45. Farber N.B., Jiang X.P., Heinkel C., and Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 7 (2002) 726-733
46. Bialer M., Levy R.H., and Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range?. Ther Drug Monit 20 (1998) 56-59
47. Rao J.S., Bazinet R.P., Rapoport S.I., and Lee H.J. Chronic administration of carbamazepine down-regulates AP-2 DNA binding activity and AP-2a protein expression in rat frontal cortex. Biol Psychiatry 61 (2007) 154-161
48. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226 (1957) 497-509
49. 14C]arachidonate to examine regional brain lipid metabolism in unanesthetized rats. J Neurosci Res 24 (1989) 413-423
50. Makrides M., Neumann M.A., Byard R.W., Simmer K., and Gibson R.A. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr 60 (1994) 189-194
51. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd ed. (1987), Academic Press, New York
52. Poddubiuk Z.M., Blumberg J.B., and Kopin I.J. Brain prostaglandin content in rats sacrificed by decapitation vs focused microwave irradiation. Experientia 38 (1982) 987-988
53. Radin N.S. Extraction of tissue lipids with a solvent of low toxicity. Methods Enzymol 72 (1981) 5-7
54. Tabachnick B.G., and Fidell L.S. Computer-Assisted Research Design and Analysis (2001), Allyn and Bacon, Boston
55. Motulsky HJ (2003): Prism 4 Statistics Guide-Statistical analyses for laboratory and clinical researchers. Available at: http://www.graphpad.com. Accessed June 15, 2007.
56. Zeise M.L., Kasparow S., and Zieglgansberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 544 (1991) 345-348
57. Gean P.W., Huang C.C., Hung C.R., and Tsai J.J. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 33 (1994) 333-336
58. Esposito G., Giovacchini G., Der M., Liow J.S., Bhattacharjee A.K., Ma K., et al. Imaging signal transduction via arachidonic acid in the human brain during visual stimulation, by means of positron emission tomography. Neuroimage 34 (2007) 1342-1351
59. 2 or lipoxygenase/cytochrome P450 pathways. Brain Res Bull 63 (2004) 485-489
60. Morri H., Ozaki M., and Watanabe Y. 5'-flanking region surrounding a human cytosolic phospholipase A2 gene. Biochem Biophys Res Commun 205 (1994) 6-11
61. 2. J Neurochem 91 (2004) 1389-1397
62. Choi S.H., Langenbach R., and Bosetti F. Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappaB pathway and downstream enzymes involved in prostaglandin biosynthesis. J Neurochem 98 (2006) 801-811
63. 2 extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J Neurochem 81 (2002) 1028-1034
64. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., et al. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 98 (2001) 1294-1299
65. 2 and centrally activates adrenomedullary outflow in rats. Neuroscience 96 (2000) 585-590
66. 2+ levels in neuronal culture. Eur J Pharmacol 219 (1992) 53-57
67. Leonard A.S., and Hell J.W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J Biol Chem 272 (1997) 12107-12115
68. Beutler A.S., Li S., Nicol R., and Walsh M.J. Carbamazepine is an inhibitor of histone deacetylases. Life Sci 76 (2005) 3107-3115
69. Crowe S.L., Movsesyan V.A., Jorgensen T.J., and Kondratyev A. Rapid phosphorylation of histone H2A.X following ionotropic glutamate receptor activation. Eur J Neurosci 23 (2006) 2351-2361
70. Bai G., and Kusiak J.W. Functional analysis of the proximal 5'-flanking region of the N-methyl-D-aspartate receptor subunit gene, NMDAR1. J Biol Chem 270 (1995) 7737-7744
71. Ryu H., Lee J., Olofsson B.A., Mwidau A., Dedeoglu A., Escudero M., et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A 100 (2003) 4281-4286
72. Costa C., Martella G., Picconi B., Prosperetti C., Pisani A., Di Filippo M., et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 37 (2006) 1319-1326
73. 2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 16 (1995) 187-198
74. McDonald J.W., and Johnston M.V. Pharmacology of N-methyl-D-aspartate-induced brain injury in an in vivo perinatal rat model. Synapse 6 (1990) 179-188
75. Abelli M., Martini C., Pini S., Gesi C., and Cassano G.B. The role of newer antiglutamatergic agents as mood-stabilizers in bipolar disorder. Curr Drug Targets 6 (2005) 607-614
76. Du J., Gray N.A., Falke C.A., Chen W., Yuan P., Szabo S.T., et al. Modulation of synaptic plasticity by antimanic agents: The role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 24 (2004) 6578-6589
77. Jakobsen S.N., and Wiborg O. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain. Brain Res 780 (1998) 46-55
78. Lesch K.P., Aulakh C.S., Tolliver T.J., Hill J.L., Wolozin B.L., and Murphy D.L. Differential effects of long-term lithium and carbamazepine administration on Gs alpha and Gi alpha protein in rat brain. Eur J Pharmacol 207 (1991) 355-359
79. Bachmann R.F., Schloesser R.J., Gould T.D., and Manji H.K. Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Mol Neurobiol 32 (2005) 173-202
80. Macdonald R.L., and McLean M.J. Mechanisms of anticonvulsant drug action. Electroencephalogr Clin Neurophysiol Suppl 39 (1987) 200-208
81. Pranzatelli M.R. Effect of antiepileptic and antimyoclonic drugs on serotonin receptors in vitro. Epilepsia 29 (1988) 412-419
82. Okada M., Hirano T., Mizuno K., Kawata Y., Wada K., Murakami T., et al. Effects of carbamazepine on hippocampal serotonergic system. Epilepsy Res 31 (1998) 187-198
83. Graumlich J.F., McLaughlin R.G., Birkhahn D., Shah N., Burk A., Jobe P.C., et al. Subcutaneous microdialysis in rats correlates with carbamazepine concentrations in plasma and brain. Epilepsy Res 40 (2000) 25-32
84. 2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology 30 (2005) 1064-1075
85. 2A/2C receptor-mediated brain signaling via arachidonic acid. Neuropsychopharmacology 30 (2005) 461-472
86. Cotman C.W., and Monaghan D.T. Anatomical organization of excitatory amino acid receptors and their properties. Adv Exp Med Biol 203 (1986) 237-252
87. 3H]TCP binding sites. Eur J Pharmacol 141 (1987) 149-152
88. Rapoport S.I., Chang M.C., and Spector A.A. Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. J Lipid Res 42 (2001) 678-685
89. Basselin M., Villacreses N.E., Langenbach R., Ma K., Bell J.M., and Rapoport S.I. Resting and arecoline-stimulated brain metabolism and signaling involving arachidonic acid are altered in the cyclooxygenase-2 knockout mouse. J Neurochem 96 (2006) 669-679
90. DeMar Jr. J.C., Lee H.J., Ma K., Chang L., Bell J.M., Rapoport S.I., et al. Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. Biochim Biophys Acta 1761 (2006) 1050-1059
91. Basselin M., Villacreses N.E., Lee H.-J., Bell J.M., and Rapoport S.I. Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats. Neurochen Res (2007) In press
92. Steppuhn K.G., and Turski L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J Pharmacol Exp Ther 265 (1993) 1063-1070
93. Turski L., Niemann W., and Stephens D.N. Differential effects of antiepileptic drugs and beta-carbolines on seizures induced by excitatory amino acids. Neuroscience 39 (1990) 799-807
94. Ormandy G.C., Song L., and Jope R.S. Analysis of the convulsant-potentiating effects of lithium in rats. Exp Neurol 111 (1991) 356-361
95. Kent S., Kernahan S.D., and Levine S. Effects of excitatory amino acids on the hypothalamic-pituitary-adrenal axis of the neonatal rat. Brain Res Dev Brain Res 94 (1996) 1-13
96. Boonstra R., and Tinnikov A.A. Increased corticosteroid binding capacity of plasma albumin but not of corticosteroid-binding globulin caused by ACTH-induced changes in free fatty acid concentrations in snowshoe hares and rabbits. J Endocrinol 156 (1998) 205-212
97. Perini G.I., Devinsky O., Hauser P., Gallucci W.T., Theodore W.H., Chrousos G.P., et al. Effects of carbamazepine on pituitary-adrenal function in healthy volunteers. J Clin Endocrinol Metab 74 (1992) 406-412
98. 2. J Neurochem 64 (1995) 2765-2772